Benzinga  3 hrs ago  Comment 
Morgan Stanley on Wednesday issued a report on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) after the company reported guidance that was below estimates. Regeneron is currently rated as Overweight with a price target of $499.00. Analysts Matthew...
Motley Fool  Feb 10  Comment 
Regeneron reported its fourth-quarter and full-year numbers this morning. Here's what investors need to know.
Benzinga  Feb 10  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported weaker-than-expected earnings for the fourth quarter. However, the company reported upbeat quarterly sales. The Tarrytown, New York-based company posted a quarterly net profit of $110.2...
Jutia Group  Feb 10  Comment 
[PR Newswire] - TARRYTOWN, N.Y., Feb. 10, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2014 and provided an update on development ... Read more on this. ...
Jutia Group  Jan 23  Comment 
[PR Newswire] - TARRYTOWN, N.Y., Jan. 23, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA ® (aflibercept) Injection has been recommended for approval by the European Committee ... Read more on this. ...
Benzinga  Jan 6  Comment 
Geoffrey Meacham of Barclays initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Tuesday with an Equal-Weight rating and $450 price target as approval and modest growth profile of key drugs are already expected by...
Forbes  Dec 31  Comment 
In early trading on Wednesday, shares of Regeneron Pharmaceuticals (REGN) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.0%.  Year to date, Regeneron Pharmaceuticals registers a 51.3% gain.
Forbes  Dec 30  Comment 
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Delta Air Lines, Inc. (NYSE: DAL) has taken over the #116 spot from Regeneron Pharmaceuticals, Inc. (NASD: REGN), according to The Online...


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki